ACRS (Aclaris Therapeutics) GF Value Rank: 1 (As of Jul. 17, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACRS Aclaris Therapeutics Inc ACRS
33 GF Score
Price $5.68
GF Value $0.44
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Aclaris Therapeutics GF Value Rank?

Aclaris Therapeutics ACRS +5.77% 33 GF Value Rank is 1 as of Jul. 17, 2026, which is 50% below its 10-year median of 2.00. GuruFocus rates ACRS with a GF Score™ of 33/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Aclaris Therapeutics has the GF Value Rank of 1.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Aclaris Therapeutics GF Value Rank Related Terms


ACRS vs RLMD, GYRE, SGP: GF Value Rank Comparison

For the Biotechnology subindustry, Aclaris Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's GF Value Rank falls into.


ACRS
33GF Score
Aclaris Therapeutics Inc ACRS
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 1 mean?
Aclaris Therapeutics (ACRS) has a GF Value Rank of 1 as of Jul. 17, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Aclaris Therapeutics and its competitors. This is 50% below median its historical median of 2.00. Over the past decade, Aclaris Therapeutics' GF Value Rank has ranged from 1.00 to 10.00.
Is Aclaris Therapeutics' GF Value Rank too high?
Aclaris Therapeutics' current GF Value Rank of 1 is 50% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Aclaris Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' GF Value Rank compare to RLMD and GYRE?
Aclaris Therapeutics' GF Value Rank of 1 can be compared against companies in the Biotechnology industry. Historically, Aclaris Therapeutics' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current GF Value Rank is 1, which is 50% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $5.68 — trading 1189.8% above its estimated fair value. The current GF Value Rank is 1, which is 50% below median its 10-year median of 2.00. Aclaris Therapeutics' overall GF Score™ is 33/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current GF Value Rank is 1 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $5.68 is trading 1189.8% above its estimated GF Value™ of $0.44. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

  • GF Value Rank: 1 (50% below median its 10-year median of 2.00)
  • GF Value™: $0.44 vs. price of $5.68 (1189.8% above fair value)
  • GF Score™: 33/100 with 10 warning signs

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aclaris Therapeutics Business Description

Other Exchanges 0H8T:UK8AT:Germany
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
33GF Score

Get the complete analysis for ACRS

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.68
Price
$0.44
GF Value